Judith Hartleib‐Geschwindner

Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion

Krister Bamberg, Ulrika Johansson, K. A. P. Edman et al. · PLoS ONE · 2018 · 71 citations · Full text

Electrolyte Disorder, Heart Failure, Renal Inflammation +20

Balcinrenone Plus Dapagliflozin in Patients with Heart Failure and Chronic Kidney Disease: Results from the Phase 2b MIRACLE Trial

Carolyn S.P. Lam, Lars Køber, Koichiro Kuwahara et al. · European Journal of Heart Failure · 2024 · 34 citations · Full text

Overexpression of AMP‐metabolizing enzymes controls adenine nucleotide levels and AMPK activation in HEK293T cells

Catheline Plaideau, Jianming Liu, Judith Hartleib‐Geschwindner et al. · The FASEB Journal · 2012 · 33 citations

Inhibition of AMP Deaminase Activity Does Not Improve Glucose Control in Rodent Models of Insulin Resistance or Diabetes

Therése Admyre, Lena Amrot-Fors, Maria Andersson et al. · Chemistry & Biology · 2014 · 27 citations · Full text

Insulin Resistance, Diabetes Management, Biochemistry +12

Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator

Fredrik Erlandsson, Muna Albayaty, Ligia Chialda et al. · British Journal of Clinical Pharmacology · 2018 · 27 citations · Full text